|
US2021120789A1
|
|
Genetically Modified Non-Human Animals
|
|
GB201915689D0
|
|
Genetically modified non-human animals
|
|
CN111296364A
|
|
Genetically modified non-human animal and application thereof
|
|
CN110590690A
|
|
Sp catalyzed by copper2Olefination reaction method for hybridization of carbon-hydrogen bond
|
|
CN110128532A
|
|
A method of preparation IVIG is produced using human plasma component II+III
|
|
CN110386929A
|
|
A kind of heterocycle mediated by copper catalyst-heterocycle C-N intersection dehydrogenation coupling reaction method
|
|
CN108853485A
|
|
A method of human blood albumin products Aluminium residual in control validity period
|
|
CN107929719A
|
|
A kind of large-scale production preparation method of the dense preparations of human plasma,freeze-dried's activated clotting factor VII
|
|
CN107782829A
|
|
One kind utilizes trishydroxymethylaminomethane in sulfate by ion chromatography biological products（Tris）Method
|
|
CN106011116A
|
|
Preparation method of human thrombin
|
|
CN105440127A
|
|
Method for preparing FEIBA (factor eight inhibitor bypassing activity) from human plasma Cohn component III serving as raw material
|
|
CN105385731A
|
|
Perfusion culture method for efficiently expressing recombinant factor VIII
|
|
CN102731642A
|
|
Production technology of high-pure Apoa-I from fourth deposit of human blood plasma component
|
|
CN102127165A
|
|
Production process for preparing high-purity ApoA-I (Apolipoprotein A-I) from precipitates of plasma fraction IV
|
|
CN101544683A
|
|
Method and substance for keeping fibrinogen activity in thermal treatment
|
|
CN101205250A
|
|
Method for preparing high-purity apolipoprotein A-I
|
